Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone | Zendy

Paul J. Fudala | Zendy; T. Peter Bridge | Zendy; Susan Herbert | Zendy; William O. Williford | Zendy; C. Nora Chiang | Zendy; Karen Jones | Zendy; Joseph F. Collins | Zendy; Dennis W. Raisch | Zendy; Paul Casadonte | Zendy; R. Jeffrey Goldsmith | Zendy; Walter Ling | Zendy; Usha Malkerneker | Zendy; Laura F. McNicholas | Zendy; John A. Renner | Zendy; Susan M. Stine | Zendy; Donald J. Tusel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Office-Based Treatment of Opiate Addiction with a Sublingual-Tablet Formulation of Buprenorphine and Naloxone

Author(s) -

Paul J. Fudala,

T. Peter Bridge,

Susan Herbert,

William O. Williford,

C. Nora Chiang,

Karen Jones,

Joseph F. Collins,

Dennis W. Raisch,

Paul Casadonte,

R. Jeffrey Goldsmith,

Walter Ling,

Usha Malkerneker,

Laura F. McNicholas,

John A. Renner,

Susan M. Stine,

Donald J. Tusel

Publication year - 2003

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa022164

Subject(s) - buprenorphine , medicine , placebo , (+) naloxone , opiate , craving , sublingual administration , anesthesia , randomized controlled trial , adverse effect , addiction , opioid , psychiatry , receptor , alternative medicine , pathology

Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone has been proposed, but its efficacy and safety have not been well studied.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research